{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:12:21Z","timestamp":1791252741199,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.eururo.2013.03.040","type":"journal-article","created":{"date-parts":[[2013,4,6]],"date-time":"2013-04-06T15:00:52Z","timestamp":1365260452000},"page":"150-158","source":"Crossref","is-referenced-by-count":122,"title":["Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08\/08)"],"prefix":"10.1016","volume":"64","author":[{"given":"Arnoud J.","family":"Templeton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Cathomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"B\u00e4rtschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelia","family":"Dr\u00f6ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Borner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Fechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Stenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Winterhalder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beat","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"Schiess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"R\u00fcschoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Thalmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Yves","family":"Dietrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruedi","family":"Aebersold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Klingbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2013.03.040_bib0005","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2013.03.040_bib0010","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.eururo.2011.01.025","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"59","author":"Mottet","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0015","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1056\/NEJMp048178","article-title":"Mechanisms of androgen-refractory prostate cancer","volume":"351","author":"Debes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2013.03.040_bib0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ccr.2010.05.026","article-title":"Integrative genomic profiling of human prostate cancer","volume":"18","author":"Taylor","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2013.03.040_bib0025","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cellsig.2009.02.024","article-title":"Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition","volume":"21","author":"Dunlop","year":"2009","journal-title":"Cell Signal"},{"key":"10.1016\/j.eururo.2013.03.040_bib0030","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1158\/0008-5472.CAN-04-3137","article-title":"Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts","volume":"65","author":"Wu","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2013.03.040_bib0035","doi-asserted-by":"crossref","first-page":"10040","DOI":"10.1158\/0008-5472.CAN-06-0802","article-title":"Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells","volume":"66","author":"Cao","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2013.03.040_bib0040","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2013.03.040_bib0045","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1002\/pros.20752","article-title":"RAD001 (everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid","volume":"68","author":"Morgan","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2013.03.040_bib0050","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S1535-6108(03)00215-0","article-title":"Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer","volume":"4","author":"Wang","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2013.03.040_bib0055","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/j.1464-410X.2012.11456.x","article-title":"Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer","volume":"110","author":"Nakabayashi","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2013.03.040_bib0060","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1073\/pnas.1013699108","article-title":"Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer","volume":"108","author":"Cima","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.eururo.2013.03.040_bib0065","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0070","doi-asserted-by":"crossref","first-page":"6396","DOI":"10.1158\/1078-0432.CCR-07-1036","article-title":"A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis","volume":"13","author":"Armstrong","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2013.03.040_bib0075","doi-asserted-by":"crossref","first-page":"142ra94","DOI":"10.1126\/scitranslmed.3003989","article-title":"Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics","volume":"4","author":"Huttenhain","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.eururo.2013.03.040_bib0080","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nbt.1661","article-title":"Options and considerations when selecting a quantitative proteomics strategy","volume":"28","author":"Domon","year":"2010","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0085","series-title":"Classification and regression trees","author":"Breiman","year":"1984"},{"key":"10.1016\/j.eururo.2013.03.040_bib0090","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.clgc.2012.05.001","article-title":"Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer","volume":"10","author":"Amato","year":"2012","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2013.03.040_bib0095","first-page":"3065","article-title":"Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer","volume":"118","author":"Carracedo","year":"2008","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2013.03.040_bib0100","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O\u2019Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2013.03.040_bib0105","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/sj.onc.1209990","article-title":"Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism","volume":"26","author":"Wan","year":"2007","journal-title":"Oncogene"},{"key":"10.1016\/j.eururo.2013.03.040_bib0110","first-page":"11","article-title":"PI3K-AKT-mTOR pathway is dominant over androgen receptor signaling in prostate cancer cells","volume":"32","author":"Kaarbo","year":"2010","journal-title":"Cell Oncol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0115","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.eururo.2013.03.040_bib0120","first-page":"3895","article-title":"Androgen receptor-mTOR crosstalk is regulated by testosterone availability: implication for prostate cancer cell survival","volume":"30","author":"Wu","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.eururo.2013.03.040_bib0125","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/path.2559","article-title":"PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer","volume":"218","author":"Sircar","year":"2009","journal-title":"J Pathol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0130","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/sj.bjc.6603924","article-title":"FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome","volume":"97","author":"Yoshimoto","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2013.03.040_bib0135","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.eururo.2011.06.038","article-title":"Novel prognostic markers in the serum of patients with castration-resistant prostate cancer derived from quantitative analysis of the Pten conditional knockout mouse proteome","volume":"60","author":"K\u00e4lin","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2013.03.040_bib0140","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.cca.2008.10.003","article-title":"Carboxypeptidase M: Multiple alliances and unknown partners","volume":"399","author":"Deiteren","year":"2009","journal-title":"Clin Chim Acta"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813002947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283813002947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T03:56:11Z","timestamp":1539748571000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283813002947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0302283813002947"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2013.03.040","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}